Skip to main content
Equibles
IOVA logo

IOVA · Iovance Biotherapeutics, Inc. · Metrics

Track IOVA — free

Use IOVA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IOVA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.90 +0.69 (+4.86%)
Russell 2000 member Rebalance outlook locked
Market Cap
$6.44B
Shares
452.97M
Volume · Oct 20 9.71M Avg daily vol (3M) 16.66M

IOVA metrics

74 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$14.86
Market cap
$6.44B

Price action

20 metrics
Price change (1W)
-2.4%
Price change (30D)
+39.5%
Price change (3M)
+183.1%
Price change (6M)
+275.9%
Price change (YTD)
+420.5%
Price change (1Y)
+551.8%
Trailing year
Price change (5Y)
-45.8%
52-week high
$14.82
52-week low
$1.81
Change from 52-week high
-4.1%
Change from 52-week low
+685.1%
Annualized volatility
105.3%
Annualized volatility (3M)
127.8%
Beta
1.3
RSI (14D)
63.2
Price vs SMA 50
+38.3%
Price vs SMA 200
+165.4%
Avg volume (3M)
16.76M
Relative volume
0.5
Average dollar volume
$154.29M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
452.97M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
18.1×
reciprocal yield 5.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
19.0×
reciprocal yield 5.3%
P / book
8.4
reciprocal yield 11.9%
FCF yield
-4.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
14.9×
reciprocal yield 6.7%
EV / revenue historical average (5Y)
14.9×
reciprocal yield 6.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
48.4%
Operating margin
-92.7%
Trailing 12 months
Net margin
-89.1%
Gross profit (TTM)
$157.29M
Operating profit (TTM)
−$301.31M
Net income (TTM)
−$289.52M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-91.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.70

Growth

11 metrics
Revenue growth YoY
+65.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$324.97M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+34.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-39.3%
Return on assets
-31.6%
Debt / equity
0.0
Current ratio
4.3
EBITDA (TTM)
−$287.79M
Free cash flow (TTM)
−$296.39M
Quick ratio
3.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$297.67M
Latest balance sheet
Cash & equivalents
$110.77M
Total assets
$915.53M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$264.18M
Capital expenditures (TTM)
$32.21M
R&D (TTM)
$267.71M
SG&A (TTM)
—
Stock compensation (TTM)
$46.72M
R&D / revenue
82.4%
Stock compensation / revenue
14.4%

Ownership (13F)

9 metrics
13F filers
294
13F filer change QoQ
+4
Institutional ownership
65.2%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
18.1%
Private-fund adviser ownership
14.8%
Active holders' share change QoQ
+1.4%
Holder tenure
14.3
Price vs estimated holder cost
-10.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
17.5%

Short interest

3 metrics
Short interest
14.3%
Latest settlement · 2.8 days to cover
Days to cover
2.8d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1425205 CUSIP 462260100 13F (30d) 24 filings 24 filers Visit website Investor relations